Nuvelo, Inc. (NUVO-NASDAQ) dropped the bomb today with the announcement that it will resume development of alfimeprase, its lead investigational product candidate for the potential treatment of multiple blood clot-related disorders such as acute ischemic stroke, catheter occlusion (CO) and acute peripheral arterial occlusion (PAO).
In addition, Nuvelo and Bayer HealthCare have agreed to terminate their collaboration. Nuvelo has agreed to waive Bayer’s obligation to provide Nuvelo twelve-months’ notice of termination in consideration of Bayer’s agreement to pay Nuvelo a lump sum of $15 million. Nuvelo has also granted Bayer the one-time option to reacquire rights to alfimeprase upon the initiation of a pivotal stroke trial, on the same terms as the original agreement with the addition of a $15 million option exercise payment from Bayer.
Nuvelo (NUVO) shares are trading down 19% at $2.70 in after-hours trading. Losing a larger partner is almost never considered a good thing on Wall Street.
Read More »